

In 2021 we carried forward what we started in 2020 and rallied another 32% adding to the 81% to the rally we saw in 2020 from the CVOID induced lows. In market parlance we marched into the new year with renewed confidence as the markets got back their momentum after the initial correction from the Omicron scare, as on date the markets have recovered ~8% from the recent lows, the smallcap indices outshone largecaps. India remains the pole star in terms of expected GDP growth and that should culminate into healthy long term investment flows.


Chinese property developers' credit ratings, Jan vs Dec 2021



As we march into a new year we are also faced a with an unprecedented dilemma both of which have two sides of it and have equal probabilities. The first is Omicron – how omicron phases itself in the country is something that will be closely watched, the experience form Africa is rather encouraging, where it peaked out in a shorter in short span of time and left little destructive trail behind, how it spans across our country over the next 15 days and how ably the healthcare system deals with it will be a key monitorable. The second is Taper – whether the US Fed and global central banks’ move ahead with a taper and its’ concurrent impact on the interest rate trajectory globally will be the other key thing that can cause volatility to spike as almost all asset classes have basked in the glory of this unprecedented liquidity infusion globally. Both these events are also interlinked as a high negative impact from COVID will lead to delay in taper and negatively impact the already fragile global economy negatively. The high number of cases in the US and European regions is a cause of concern which could extend this on and off kind of economic scenario by a few more months.


The Chinese real estate tussle is in its final leg as huge redemptions are due during the current month and any negative outcome could raise fears of a global contagion like scenario. How the COVID related curbs will impact the logistic chains and inflation is another issue that needs to be closely monitored.

S. Africa - Number of people ventilated (charted) is running at ~20% of the peak during the delta.



Our take is that OMICRON may not be as deadly as earlier thought hence inflation and supply bottlenecks that we have been seeing for some time now should gradually ease as we step further into the current year and 2022 maybe be the first years since COVID that may provide us with a normalised base year to make YOY comparisons for macro and micro economic indicators as well as the numbers reported companies as the base year distortions have plagued economic data for both 2020 & 2021. The variable to care about will not be the taper but the speed of taper and if central banks can avoid negative surprises of sudden changes in their taper programmes, equity markets globally would happily celebrate the end of COVID. As we try to crystal gaze into the new year the ideal strategy should be to stick to a stock specific approach in equity investing and carefully select a basket of stocks with sound fundamentals as most companies have deleveraged over the last 2 years leaving little scope of corporate stress, though the MSME and retail space could surprise slightly negatively. On the debt side short duration remains the idle choice since the rate trajectory settles and credit risk is certainly not advised given the amount of expected turbulence. Gold should continue to remain an ideal diversification bet in the portfolios to use dips in the markets to rebalance the weightage into equities as the occasional adjustment or corrections happen.


“A 10% decline in the market is fairly common—it happens about once a year. Investors who realize this are less likely to sell in a panic, and more likely to remain invested, benefitting from the wealth building power of stocks.” - Christopher Davis



Sharad Avasthi
Vice President – PCG, SMIFS Ltd.


Profile: Conservative

Scheme	1 Yr Return(%)	3 Year Return(%)	5 Year Return(%)
HDFC Ultra Short Term Fund Reg (G)	3.56	5.88	0.00
Canara Robeco Emerging equities Reg (G)	37.82	23.82	20.39
Axis Bluechip Fund (G)	22.36	20.60	20.54
Kotak Bond STP (G)	3.28	7.55	6.78
Kotak Gold Fund (G)	-4.62	14.07	10.47




Profile: Moderate






Scheme	1 Yr Return(%)	3 Year Return(%)	5 Year Return(%)
Aditya Birla SL Short Term Fund Reg (G)	3.82	7.74	6.97
PGIM India Mid Cap Opp Fund Reg (G)	63.16	36.73	23.63
Kotak Gold Fund (G)	-4.62	14.07	10.47
Canara Robeco Bluechip Equity Fund (G)	26.03	22.21	19.32




Profile: Aggressive

Scheme	1 Yr Return(%)	3 Year Return(%)	5 Year Return(%)
ICICI Pru Smallcap Fund Reg (G)	60.69	30.16	19.20
HDFC Small Cap Fund (G)	66.26	22.34	21.48
Kotak Gold Fund (G)	-4.62	14.07	10.47
SBI Magnum Ultra Short Duration Fund Reg (G)	3.40	5.70	6.33







GST Collection (Rs Bn)



E Way Bill



Trade Deficit



HEAD OFFICE:

5F, Vaibhav, 4Lee Road, Kolkata -700020, India

Sharad Avasthi

Contact No.: +91 33 3051 5400 | +91 33 4011 5400 | Email ID: research@smifs.com

Disclaimer:

Any document, including this report, which is prepared by the research team of SMIFS is circulated for the purpose of information only to the intended recipient and should not be replicated or quoted or circulated to any person/corporate or legal entities in any form. This document/ documents/ reports/ opinion should not be interpreted as an investment/ taxation/ legal advice. While the information contained in the report has been procured in good health, from sources considered/ believed to be reliable, all/ part of the statement/ statements/ opinion/ opinions/ view/views in the report may not be considered to be complete or accurate. Therefore, it should only be relied upon at the recipients own risk.

Research Analysts/ Economists/ Advisors/ Investment Strategies or any other spokespersons of the company (SMIFS) are often sought after for expressing their views on print/ electronic/ web media. The views expressed are purely based on their assumption/ understanding on fundamental approach/ technical and historic facts on the subject. The views expressed should not be constructed as an offer to buy/ sell or hold equity/ commodity/ currencies or their derivatives. The views/ opinions expressed is for information purpose only, and may change due to underlying factor, related or unrelated or other market conditions and may or may not be updated.

SMIFS, its subsidiaries, or any of its directors, employees, agents, and representatives shall not be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information/ research reports/ opinions expressed.

Disclosure: Clients/ associates of SMIFS Group may be holding positions in equities or their derivatives on which the research report is made or opinion is formed or views are expressed in print or electronic media. We ensure all compliance is adhered to with this report/ reports/ opinion or views expressed.

Analyst ownership of the stock- NIL

Analyst's dependent relatives' ownership in the stock- NIL

Analyst Certification: *The matter related to the report has been taken from sources believed reliable and the views expressed about the subject or issues in this report accurately reflect the personal views of the analyst/analysts. SMIFS does not compensate partly or in full, directly or indirectly, related to specific recommendations or views expressed by the research analysts'/market strategies/ Portfolio Managers.*

REGISTRATION as required under SEBI (Research Analyst) Regulation 2014 has been granted by Securities & Exchange Board of India (SEBI), registration number being INH300001474.

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Tel.: +91 33 6634 5408, / Fax: 91 33 22893401

Website: www.smifs.com

For queries related to compliance of the report, please contact:

Sudipto Datta, Compliance Officer

Contact No.: +91 33 66345414 | 4011 5414

Email Id.: compliance@smifs.com | sudipta@smifs.com